Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. The Effectiveness and Cost-Effectiveness of Screening for HIV in Migrants in the EU/EEA: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Why prescribe exercise as therapy in type 2 diabetes? We have a pill for that!

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. 2018 update of the EULAR recommendations for the management of Behçet's syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Christina Greenaway
  • Iuliia Makarenko
  • Claire Nour Abou Chakra
  • Balqis Alabdulkarim
  • Robin Christensen
  • Adam Palayew
  • Anh Tran
  • Lukas Staub
  • Manish Pareek
  • Joerg J Meerpohl
  • Teymur Noori
  • Irene Veldhuijzen
  • Kevin Pottie
  • Francesco Castelli
  • Rachael L Morton
Vis graf over relationer

Chronic hepatitis C (HCV) is a public health priority in the European Union/European Economic Area (EU/EEA) and is a leading cause of chronic liver disease and liver cancer. Migrants account for a disproportionate number of HCV cases in the EU/EEA (mean 14% of cases and >50% of cases in some countries). We conducted two systematic reviews (SR) to estimate the effectiveness and cost-effectiveness of HCV screening for migrants living in the EU/EEA. We found that screening tests for HCV are highly sensitive and specific. Clinical trials report direct acting antiviral (DAA) therapies are well-tolerated in a wide range of populations and cure almost all cases (>95%) and lead to an 85% lower risk of developing hepatocellular carcinoma and an 80% lower risk of all-cause mortality. At 2015 costs, DAA based regimens were only moderately cost-effective and as a result less than 30% of people with HCV had been screened and less 5% of all HCV cases had been treated in the EU/EEA in 2015. Migrants face additional barriers in linkage to care and treatment due to several patient, practitioner, and health system barriers. Although decreasing HCV costs have made treatment more accessible in the EU/EEA, HCV elimination will only be possible in the region if health systems include and treat migrants for HCV.

OriginalsprogEngelsk
TidsskriftInternational Journal of Environmental Research and Public Health
Vol/bind15
Tidsskriftsnummer9
ISSN1661-7827
DOI
StatusUdgivet - 14 sep. 2018

ID: 55276722